Rubicon Global Research, LLC Reiterates its Strong-Buy Rating on Forbes Medi-Tech.

PORTLAND, Ore. -- Recent weakness in Forbes Medi-Tech (NASDAQ:FMTI) creates an excellent buying opportunity. FMTI shares have declined in recent days as investors struggle to digest the recent PIPE financing and the Company's 3rd quarter, September 2005 earnings release. Furthermore, the absence of new food contracts, and concerns over potential contract renewals on the nutraceutical side of the business have created some apparent nervousness among investors. We believe the weakness in the shares represents a severe overreaction to fundamental developments, and that the business is tracking to our financial expectation. As a result, we are maintaining our current model and investment thesis. Thus, we recommend investors utilize this opportunity to buy shares in this exciting play on the multi-billion dollar, fast-growing cholesterol lowering market.

Note: Rubicon Global Research was not involved nor participated in the company's recent private placement.

A more comprehensive update note published on November 21, 2005, by Rubicon Global Research, LLC is currently available.

A detailed full investment report published on July 5, 2005, by Rubicon Global Research, LLC is currently available.

Rubicon Global Research, LLC is a wholly-owned subsidiary of Rubicon Global Holdings, LLC, a registered NASD company.